Literature DB >> 11528567

Community-acquired bacterial meningitis in adults: categorization of causes and timing of death.

D A McMillan1, C Y Lin, S I Aronin, V J Quagliarello.   

Abstract

The relationship between cause and timing of death in 294 adults who had been hospitalized with community-acquired bacterial meningitis was investigated. For 74 patients with community-acquired bacterial meningitis who died during hospitalization, the underlying and immediate causes of death were identified according to the criteria of the World Health Organization and National Center for Health Statistics. Patients were classified into 3 groups: category I, in which meningitis was the underlying and immediate cause of death (59% of patients; median duration of survival, 5 days); category II, in which meningitis was the underlying but not immediate cause of death (18%; median duration of survival, 10 days); and category III, in which meningitis was neither the underlying nor immediate cause of death (23%; median duration of survival, 32 days). In a substantial proportion of adults hospitalized with community-acquired bacterial meningitis, meningitis was neither the immediate nor the underlying cause of death. A 14-day survival end point discriminated between deaths attributable to meningitis and those with another cause.

Entities:  

Mesh:

Year:  2001        PMID: 11528567     DOI: 10.1086/322612

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

1.  Laboratory-based surveillance for patients with acute meningitis in Sudan, 2004-2005.

Authors:  S Afifi; M S Karsany; M Wasfy; G Pimentel; A Marfin; R Hajjeh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-11-12       Impact factor: 3.267

2.  Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation.

Authors:  E Bingen; C Levy; E Varon; F de La Rocque; M Boucherat; P d'Athis; Y Aujard; R Cohen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-30       Impact factor: 3.267

Review 3.  Corticosteroids for acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Peter McIntyre; Kameshwar Prasad; Diederik van de Beek
Journal:  Cochrane Database Syst Rev       Date:  2015-09-12

Review 4.  Management of meningitis due to antibiotic-resistant Acinetobacter species.

Authors:  Baek-Nam Kim; Anton Y Peleg; Thomas P Lodise; Jeffrey Lipman; Jian Li; Roger Nation; David L Paterson
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

5.  Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone.

Authors:  U Egermann; Z Stanga; A Ramin; F Acosta; A Stucki; P Gerber; M Cottagnoud; P Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

6.  Outcomes and Health Care Resource Utilization of Adult Bacterial Meningitis in the United States.

Authors:  Musa Kiyani; Sarah E Hodges; Syed M Adil; Lefko T Charalambous; Beiyu Liu; Hui-Jie Lee; Beth Parente; John R Perfect; Shivanand P Lad
Journal:  Neurol Clin Pract       Date:  2021-04

7.  Cerebral infarction in adults with bacterial meningitis.

Authors:  Ewout S Schut; Marjolein J Lucas; Matthijs C Brouwer; Mervyn D I Vergouwen; Arie van der Ende; Diederik van de Beek
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.532

8.  The use of dexamethasone in bacterial meningitis in children and adults: a retrospective analysis.

Authors:  An-Sophie Cornelis; Said Hachimi-Idrissi
Journal:  ISRN Pediatr       Date:  2011-12-28

9.  Community-acquired bacterial meningitis in alcoholic patients.

Authors:  Martijn Weisfelt; Jan de Gans; Arie van der Ende; Diederik van de Beek
Journal:  PLoS One       Date:  2010-02-08       Impact factor: 3.240

10.  The spectrum of acute bacterial meningitis in elderly patients.

Authors:  Pere Domingo; Virginia Pomar; Natividad de Benito; Pere Coll
Journal:  BMC Infect Dis       Date:  2013-02-27       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.